optimizing immunochemistry (IHC) stains and developing multiplexed techniques

KalGene is developing a promising Alzheimer’s disease therapeutic in collaboration with its strategic partner.

Today, an estimated 500,000 Canadians* and 5 million Americans** are living with Alzheimer’s disease. In 2014, the direct costs of caring for people living with the disease are estimated to total well over $210 billion in the U.S. alone. It is estimated that up to 16 million people will have Alzheimer's disease by 2050 in the U.S.

The Alzheimer's disease therapeutics and diagnostics market will reach $9.6 billion in 2014 with revenue showing strong overall growth to 2024, particularly beyond 2018. Overall, the forecast for Alzheimer's disease, including disease-modifying therapeutics, therapeutics that treat related symptoms, diagnostics and imaging, is set to increase exponentially. ***

Preventing Alzheimer's disease progression remains a critical unmet need for millions of people in Canada and worldwide. KalGene Pharmaceutical's innovations in the discovery, development, and commercialization of novel Alzheimer's disease therapeutics will fundamentally improve patient treatment, quality of life, and disease management.

KalGene’s goal is to become a leader in the worldwide effort to modify disease treatment, focusing on very earlier clinical signs of dementia, before neural damage causes progressive destruction. To achieve our goal, we will be collaborating with clinicians, scientists, and clinical centers worldwide .

*Alzheimer Society of Toronto
**Alzheimer’s Association
***Alzheimer's Disease Therapeutics and Diagnostics Market Forecast 2014-2024, visiongain